Effectiveness of Thrice Weekly Ezetimibe

Carmelo Venero, Jose V. Venero, Richard L. Seip, Paul D. Thompson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Ezetimibe is usually dosed daily, but its 22-hour elimination half-life permits significant cholesterol reduction with less frequent dosing. The aim of this study was to examine lipid changes in 33 patients treated with thrice-weekly ezetimibe for ≥1 month, who had pre- and postezetimibe lipid levels and no other concurrent changes in their lipid treatment. Ninety-four percent of the patients were treated with ezetimibe because they experienced myalgias, elevated transaminase levels, or gastrointestinal intolerance with higher doses of other lipid-lowering agents. Total cholesterol decreased by 15% (-36 ± 28 mg/dl, p <0.001) and low-density lipoprotein cholesterol by 20% (-30 ± 25 mg/dl, p <0.001) during 58 ± 50 days of treatment. Most patients (85%) tolerated the treatment, and many (48%) achieved their low-density lipoprotein cholesterol goals. In conclusion, thrice-weekly ezetimibe decreases total and low-density lipoprotein cholesterol and is well tolerated. It is a viable treatment for patients intolerant of other lipid-lowering medications.

Original languageEnglish (US)
Pages (from-to)1205-1206
Number of pages2
JournalAmerican Journal of Cardiology
Volume102
Issue number9
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

Lipids
LDL Cholesterol
Cholesterol
Myalgia
Therapeutics
Transaminases
Half-Life
Ezetimibe

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Effectiveness of Thrice Weekly Ezetimibe. / Venero, Carmelo; Venero, Jose V.; Seip, Richard L.; Thompson, Paul D.

In: American Journal of Cardiology, Vol. 102, No. 9, 01.11.2008, p. 1205-1206.

Research output: Contribution to journalArticle

Venero, Carmelo ; Venero, Jose V. ; Seip, Richard L. ; Thompson, Paul D. / Effectiveness of Thrice Weekly Ezetimibe. In: American Journal of Cardiology. 2008 ; Vol. 102, No. 9. pp. 1205-1206.
@article{b927b23e19e84150b670f4fe1f19222b,
title = "Effectiveness of Thrice Weekly Ezetimibe",
abstract = "Ezetimibe is usually dosed daily, but its 22-hour elimination half-life permits significant cholesterol reduction with less frequent dosing. The aim of this study was to examine lipid changes in 33 patients treated with thrice-weekly ezetimibe for ≥1 month, who had pre- and postezetimibe lipid levels and no other concurrent changes in their lipid treatment. Ninety-four percent of the patients were treated with ezetimibe because they experienced myalgias, elevated transaminase levels, or gastrointestinal intolerance with higher doses of other lipid-lowering agents. Total cholesterol decreased by 15{\%} (-36 ± 28 mg/dl, p <0.001) and low-density lipoprotein cholesterol by 20{\%} (-30 ± 25 mg/dl, p <0.001) during 58 ± 50 days of treatment. Most patients (85{\%}) tolerated the treatment, and many (48{\%}) achieved their low-density lipoprotein cholesterol goals. In conclusion, thrice-weekly ezetimibe decreases total and low-density lipoprotein cholesterol and is well tolerated. It is a viable treatment for patients intolerant of other lipid-lowering medications.",
author = "Carmelo Venero and Venero, {Jose V.} and Seip, {Richard L.} and Thompson, {Paul D.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1016/j.amjcard.2008.06.050",
language = "English (US)",
volume = "102",
pages = "1205--1206",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Effectiveness of Thrice Weekly Ezetimibe

AU - Venero, Carmelo

AU - Venero, Jose V.

AU - Seip, Richard L.

AU - Thompson, Paul D.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Ezetimibe is usually dosed daily, but its 22-hour elimination half-life permits significant cholesterol reduction with less frequent dosing. The aim of this study was to examine lipid changes in 33 patients treated with thrice-weekly ezetimibe for ≥1 month, who had pre- and postezetimibe lipid levels and no other concurrent changes in their lipid treatment. Ninety-four percent of the patients were treated with ezetimibe because they experienced myalgias, elevated transaminase levels, or gastrointestinal intolerance with higher doses of other lipid-lowering agents. Total cholesterol decreased by 15% (-36 ± 28 mg/dl, p <0.001) and low-density lipoprotein cholesterol by 20% (-30 ± 25 mg/dl, p <0.001) during 58 ± 50 days of treatment. Most patients (85%) tolerated the treatment, and many (48%) achieved their low-density lipoprotein cholesterol goals. In conclusion, thrice-weekly ezetimibe decreases total and low-density lipoprotein cholesterol and is well tolerated. It is a viable treatment for patients intolerant of other lipid-lowering medications.

AB - Ezetimibe is usually dosed daily, but its 22-hour elimination half-life permits significant cholesterol reduction with less frequent dosing. The aim of this study was to examine lipid changes in 33 patients treated with thrice-weekly ezetimibe for ≥1 month, who had pre- and postezetimibe lipid levels and no other concurrent changes in their lipid treatment. Ninety-four percent of the patients were treated with ezetimibe because they experienced myalgias, elevated transaminase levels, or gastrointestinal intolerance with higher doses of other lipid-lowering agents. Total cholesterol decreased by 15% (-36 ± 28 mg/dl, p <0.001) and low-density lipoprotein cholesterol by 20% (-30 ± 25 mg/dl, p <0.001) during 58 ± 50 days of treatment. Most patients (85%) tolerated the treatment, and many (48%) achieved their low-density lipoprotein cholesterol goals. In conclusion, thrice-weekly ezetimibe decreases total and low-density lipoprotein cholesterol and is well tolerated. It is a viable treatment for patients intolerant of other lipid-lowering medications.

UR - http://www.scopus.com/inward/record.url?scp=54549122575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54549122575&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2008.06.050

DO - 10.1016/j.amjcard.2008.06.050

M3 - Article

C2 - 18940292

AN - SCOPUS:54549122575

VL - 102

SP - 1205

EP - 1206

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -